McMullen is a technology company.
McMullen has raised $500K across 1 funding round.
McMullen has raised $500K in total across 1 funding round.
McMullen has raised $500K in total across 1 funding round.
McMullen's investors include 125 Ventures, Cake Ventures, MaC Venture Capital.
Agilent Technologies, led by President and CEO Michael McMullen, is a global leader in life sciences, diagnostics, and applied chemical markets, providing instruments, software, services, and consumables for laboratory workflows.[1][3] The company supports pharma, biotech, and research clients by advancing scientific discoveries, ensuring pharmaceutical safety, and reducing drug development costs through tools like analytical instrumentation, lab automation, AI-driven workflows, and the integrated CrossLab solution.[1][3] Serving over 100 countries with about 12,000 employees and $4.0 billion in fiscal 2014 revenues, Agilent focuses on operational efficiency amid economic pressures, enabling clients to prioritize innovation over administrative tasks.[3]
Key offerings include real-time live cell analysis for cell and gene therapies, nucleic acid therapeutics workflows (e.g., mRNA, siRNA), and strengths in chromatography like GC/MS and LC, positioning it as a premier lab partner.[1][2]
Agilent Technologies spun off from Hewlett-Packard Co. in 1999 as a diversified technology firm, later transforming into a focused leader in life sciences, diagnostics, and applied markets.[3] Michael McMullen joined HP (Agilent's predecessor) with over 30 years of experience, starting with revitalizing mass spectrometry products like single- and triple-quadrupole GC/MS in the 1990s, followed by expanding the instrument business in Asia—particularly China—where chromatography became a core strength.[2][3]
Appointed Agilent's third president and CEO in 2015 at age 53, McMullen had previously led the Agilent CrossLab Group (2009-2014) and served as president and COO, overseeing life sciences, chemical analysis, diagnostics, and global operations.[3] His career evolved from product development and overseas roles (e.g., Japan with ICP/MS) to driving Asia growth, humanizing Agilent's shift from HP's electrical measurement roots (oscilloscopes, counters) to intuitive, premium lab instruments.[2][3]
Agilent rides the cell/gene therapy and nucleic acid therapeutics wave, providing critical tools for drug discovery amid post-pandemic biotech slumps, where economic pressures demand efficiency.[1] Timing aligns with rising needs for real-time cell analysis and streamlined workflows, countering clinical trial dependencies and accelerating innovations in chronic disease treatments like cancer.[1]
Market forces favoring Agilent include lab digitization (AI, automation), global R&D growth in Asia, and demand for end-to-end solutions in life sciences/diagnostics—areas where it holds strong positions from HP's legacy.[2][3] It influences the ecosystem by enabling researchers to focus on science, not operations, fostering broader advances in pharma efficiency and therapeutic development.[1]
Agilent under McMullen is poised to expand in AI-enhanced lab management, cell therapies, and nucleic acid drugs, capitalizing on its CrossLab integration for sustained growth in life sciences.[1][3] Trends like automated workflows and Asia's R&D boom will shape its path, potentially amplifying influence as biotech rebounds.[2]
As a transformed HP spin-off now dominating lab innovation, Agilent exemplifies how focused execution turns legacy strengths into ecosystem leadership—primed for deeper impact in precision medicine.[1][2][3]
McMullen has raised $500K across 1 funding round. Most recently, it raised $500K Seed in November 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2022 | $500K Seed | 125 Ventures, Cake Ventures, MaC Venture Capital |